Literature DB >> 24112138

Analysis of the factors affecting the formation of the microbiome associated with chronic osteomyelitis of the jaw.

A Goda1, F Maruyama, Y Michi, I Nakagawa, K Harada.   

Abstract

Chronic osteomyelitis of the jaw (COMJ) is one of the most intractable diseases among head and neck infections. Antimicrobial agents are routinely administered for COMJ without sufficient bacterial information, resulting in frequent treatment failures. To improve our knowledge of the bacterial aetiology of COMJ and to assist in the development of effective treatments, we performed a comprehensive analysis of the microbiome. Sixteen patients with four clinical types of COMJ (four with suppurative osteomyelitis, three with osteoradionecrosis of the jaw, four with primary chronic osteomyelitis, and five with bisphosphonate-related osteonecrosis of the jaw) were enrolled in this study. Bone samples were subjected to bacterial community comparisons by 16S rRNA gene pyrosequencing. As a result, we clarified that COMJ was caused by a far greater range of bacterial species (12 phyla and 163 genera) than previously reported. Moreover, the bacterial structures in COMJ changed dramatically with disease stage and the condition of the affected bone. Multiple correlation analyses revealed that sequestration and bone exposure could affect the community structure. On the basis of these factors, we reclassified COMJ into three clinical stages: I, inflamed or sclerotic bone without exposure; II, sequestrum without exposure; and III, exposed sequestrum. In stage II, the bacterial diversity was significantly lower, and the anaerobe genera Fusobacterium, Tannerella (formerly Bacteroides) and Porphyromonas were more abundant, than observed during other stages. Because these bacteria habitually reside in any clinical stage, they were considered to constitute the core microbiome of COMJ. Targeting these bacteria should lead to the development of effective preventive measures and cures.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  16S rRNA gene; chronic osteomyelitis of the jaw; core microbiome; metadata; pyrosequencing

Mesh:

Substances:

Year:  2013        PMID: 24112138     DOI: 10.1111/1469-0691.12400

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  Rhizobacterial Community Structures Associated with Native Plants Grown in Chilean Extreme Environments.

Authors:  Milko A Jorquera; Fumito Maruyama; Andrew V Ogram; Oscar U Navarrete; Lorena M Lagos; Nitza G Inostroza; Jacquelinne J Acuña; Joaquín I Rilling; María de La Luz Mora
Journal:  Microb Ecol       Date:  2016-07-13       Impact factor: 4.552

2.  Distinct interacting core taxa in co-occurrence networks enable discrimination of polymicrobial oral diseases with similar symptoms.

Authors:  Takahiko Shiba; Takayasu Watanabe; Hirokazu Kachi; Tatsuro Koyanagi; Noriko Maruyama; Kazunori Murase; Yasuo Takeuchi; Fumito Maruyama; Yuichi Izumi; Ichiro Nakagawa
Journal:  Sci Rep       Date:  2016-08-08       Impact factor: 4.379

3.  The microbiome of diabetic foot osteomyelitis.

Authors:  S A V van Asten; J La Fontaine; E J G Peters; K Bhavan; P J Kim; L A Lavery
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-15       Impact factor: 3.267

4.  Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw.

Authors:  Smruti Pushalkar; Xin Li; Zoya Kurago; Lalitha V Ramanathapuram; Satoko Matsumura; Kenneth E Fleisher; Robert Glickman; Wenbo Yan; Yihong Li; Deepak Saxena
Journal:  Int J Oral Sci       Date:  2014-08-08       Impact factor: 6.344

5.  Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity.

Authors:  Madina Kozhieva; Natalia Naumova; Tatiana Alikina; Alexey Boyko; Valentin Vlassov; Marsel R Kabilov
Journal:  BMC Microbiol       Date:  2019-12-30       Impact factor: 3.605

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.